Vaxcyte Announces VAX-31 Vaccine Meets All Phase III Trial Endpoints

Key Facts

1Vaxcyte announced that its VAX-31 vaccine met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial.

Vaxcyte announced that its VAX-31 vaccine met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial. Defense World reported that the study involved over 4,000 U.S. adults to evaluate the safety and immunogenicity of the investigational vaccine.

PCVX closed at $73.82 on October 5, 2026, with the session seeing a range between a low of $71.6 and a high of $90.75. The 31-valent pneumococcal conjugate vaccine is designed to prevent invasive pneumococcal disease and compete with existing clinical standards.